| Trial ID: | L2219 |
| Source ID: | NCT02131948
|
| Associated Drug: |
Intranasal Insulin
|
| Title: |
Regulation of Endogenous Glucose Production by Brain Insulin Action
|
| Acronym: |
Nasal insulin
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Insulin Resistance, Diabetes
|
| Interventions: |
DRUG: Intranasal insulin|DRUG: Intranasal placebo
|
| Outcome Measures: |
Primary: Endogenous glucose production, Effects of intranasal insulin and placebo on endogenous glucose production will be assessed, 8 hours |
|
| Sponsor/Collaborators: |
Sponsor: University Health Network, Toronto
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
8
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2013-11
|
| Completion Date: |
2014-07
|
| Results First Posted: |
|
| Last Update Posted: |
2015-12-02
|
| Locations: |
Tornto General Hospital, UHN, Toronto, Ontario, M5G 1L7, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02131948
|
